Evaluation of the effectiveness of complex medical rehabilitation of patients with polyposis rhinosinusitis associated with atopic dermatitis using ICF

Abstract

BACKGROUND: In medical rehabilitation of patients with polyposis rhinosinusitis, aimed at solving the urgent strategic task of public health care to achieve and maintain an optimal level of functioning of persons suffering from partial disability through the development of effective methods of restoration of impaired functions and prevention of complications, there is a need to adequately assess the effectiveness of the measures taken. In this regard, it should be noted that the International Classification of Functioning, Disability and Health (ICF) serves as the gold standard for assessing the patient's quality of life and the effectiveness of rehabilitation measures. The category of human functioning acts as a system-forming basis and starting point of the patient's rehabilitation process in the ICF. In practice, the ICF is based on the biopsychosocial model of health (disease) assessment, which considers psychological and social factors of health (disease) and biological disorders in close interrelated unity.

AIM: To evaluate the effectiveness of complex medical rehabilitation of patients with polyposis rhinosinusitis associated with atopic dermatitis using dynamic changes in the main domains of the ICF.

MATERIALS AND METHODS: The study was performed with 89 patients with polyposis rhinosinusitis associated with atopic dermatitis. All patients were divided into 4 groups by simple fixed randomisation. The first group (control, n=22) received only basic therapy, including endonasal application of nasonex 2 doses 2 times a day, daily twice daily washing of the nasal mucosa, as well as the use of desensitising (antihistamines, topical glucocorticoids and moisturising and emollient agents) and detoxifying agents. Patients in the second group (comparison group 1, n=22) were additionally subcutaneously administered dupilumab at a dose of 300 mcg once a fortnight. In the third group (comparison group 2, n=23) against the background of dupilumab administration the combined effect of alternating magnetic field and low-intensity laser radiation of red spectrum was performed. Patients of the fourth group (the main group, n=22) received a course of phototherapy in addition to the scope of treatment of patients of the third group. The results of medical rehabilitation of patients with polyposis rhinosinusitis associated with atopic dermatitis were evaluated according to the dynamics of specialised categories of ICF, which most accurately characterise the patient's condition from the perspective of the biopsychosocial model of the disease.

RESULTS: Changes in the estimated parameters of ICF at comparable initial values had different character and were determined by the scheme of medical rehabilitation. Minimal changes were recorded in the control group. The use of dupilumab was accompanied by positive dynamics of the parameters after 1 month with a significant increase in the shifts after 6 months, indicating the recovery of a number of mental and physical functions, as well as the ICF categories characterising the organism structures, activity and participation of the patient. Supplementation of biological therapy with course magnetolaser influence was accompanied by an increase in positive changes, which were confirmed in 6 months after rehabilitation. The maximum dynamics of the considered ICF categories was noted in the 4th group, where dupilumab administration was supplemented with complex use of therapeutic physical factors.

CONCLUSION: The obtained results prove the high informativeness of the system approach realised with the help of ICF in assessing the effectiveness of medical rehabilitation measures. The comparative evaluation of rehabilitation results convincingly showed the advantages of the complex programme including dupilumab target therapy in combination with physiotherapeutic effects.

Keywords

atopic dermatitis / dupilumab / low-intensity laser radiation / alternating magnetic field / polyposis rhinosinusitis / phototherapy / International Classification of Functioning, Disability and Health Disorders

References

[1] Chen S, Zhou A, Emmanuel B, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897–1911. EDN: HONOIL doi: 10.1080/03007995.2020.1815682

[2] Chen S., Zhou A., Emmanuel B., et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis // Curr Med Res Opin. 2020. Vol. 36, N 11. P. 1897–1911. EDN: HONOIL doi: 10.1080/03007995.2020.1815682

[3] Bai J, Huang JH, Price CP, et al. Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2022;150(2):352–361.e7. EDN: RGPCTB doi: 10.1016/j.jaci.2022.02.029

[4] Bai J., Huang J.H., Price C.P., et al. Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps // J Allergy Clin Immunol. 2022. Vol. 150, N 2. P. 352–361.e7. EDN: RGPCTB doi: 10.1016/j.jaci.2022.02.029

[5] Takabayashi T, Schleimer RP. Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin. J Allergy Clin Immunol. 2020;145(3):740–750.doi: 10.1016/j.jaci.2020.01.027

[6] Takabayashi T., Schleimer R.P. Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin // J Allergy Clin Immunol. 2020. Vol. 145, N 3. P. 740–750. doi: 10.1016/j.jaci.2020.01.027

[7] Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565–572. doi: 10.1016/j.jaip.2016.04.012

[8] Stevens W.W., Schleimer R.P., Kern R.C. Chronic rhinosinusitis with nasal polyps // J Allergy Clin Immunol Pract. 2016. Vol. 4, N 4. P. 565–572. doi: 10.1016/j.jaip.2016.04.012

[9] Martinez-Paredes JF, Donaldson AM, Marino M, et al. Sinonasal outcomes using oral corticosteroids in patients with chronic rhinosinusitis with nasal polyps and positive sinonasal cultures. Int Arch Otorhinolaryngol. 2022;27(2):e286–e295. EDN: MIBNFP doi: 10.1055/s-0042-1743275

[10] Martinez-Paredes J.F., Donaldson A.M., Marino M., et al. Sinonasal outcomes using oral corticosteroids in patients with chronic rhinosinusitis with nasal polyps and positive sinonasal cultures // Int Arch Otorhinolaryngol. 2022. Vol. 27, N 2. P. e286–e295. EDN: MIBNFP doi: 10.1055/s-0042-1743275

[11] Calus L, Van Bruaene N, Bosteels C, et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clin Transl Allergy. 2019;(9):30. doi: 10.1186/s13601-019-0269-4

[12] Calus L., Van Bruaene N., Bosteels C., et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis // Clin Transl Allergy. 2019. N 9. P. 30. doi: 10.1186/s13601-019-0269-4

[13] Martin-Jimenez D, Moreno-Luna R, Callejon-Leblic A, et al. Long-term clinical outcomes in patients with chronic rhinosinusitis with nasal polyps associated with expanded types of endoscopic sinus surgery. J Clin Med. 2024;13(3):866. doi: 10.3390/jcm13030866

[14] Martin-Jimenez D., Moreno-Luna R., Callejon-Leblic A., et al. Long-term clinical outcomes in patients with chronic rhinosinusitis with nasal polyps associated with expanded types of endoscopic sinus surgery // J Clin Med. 2024. Vol. 13, N 3. P. 866. doi: 10.3390/jcm13030866

[15] Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020;124(4):326–332. doi: 10.1016/j.anai.2019.12.001

[16] Laidlaw T.M., Buchheit K.M. Biologics in chronic rhinosinusitis with nasal polyposis // Ann Allergy Asthma Immunol. 2020. Vol. 124, N 4. P. 326–332. doi: 10.1016/j.anai.2019.12.001

[17] Health of a healthy person: Scientific foundations of healthcare organization, restorative and environmental medicine. Management. Ed. A.N. Razumova, V.I. Starodubova, A.I. Vyalkova, Yu.A. Rakhmanina, et al. 3rd revised and updated. Moscow: International University of Rehabilitation Medicine; 2016. 624 p. (In Russ).

[18] Здоровье здорового человека: научные основы организации здравоохранения, восстановительной и экологической медицины. Руководство / под ред. А.Н. Разумова, В.И. Стародубова, А.И. Вялкова, Ю.А. Рахманина и др. 3-е изд., перераб. и доп. Москва: Международный университет восстановительной медицины, 2016. 624 с.

[19] Pelishenko TG, Kruglova LS, Nagornev SN. Features of complex medical rehabilitation of patients with polyposis rhinosinusitis associated with atopic dermatitis. Russ J Environmental Rehabilitat Med. 2023;(3):14−25. (In Russ).

[20] Пелишенко Т.Г., Круглова Л.С., Нагорнев С.Н. Особенности проведения комплексной медицинской реабилитации пациентов с полипозным риносинуситом, ассоциированным с атопическим дерматитом // Russ J Environmental Rehabilitat Med. 2023. № 3. С. 14–25.

[21] Certificate of state registration of the database No. 2022622436, Russian Federation. Kotenko KV, Korchazhkina NB, Eremin II, et al. Database of scientific research on the use of photo and laser therapy in the treatment of postoperative scars: No. 2022622380: application. 09/29/2022: publ. 10/06/2022; applicant Russian Scientific Center for Surgery named after Academician B.V. Petrovsky. EDN: SWAYKS

[22] Свидетельство о государственной регистрации базы данных № 2022622436, Российская Федерация. Котенко К.В., Корчажкина Н.Б., Еремин И.И., и др. База данных научных исследований по применению фото- и лазеротерапии при лечении послеоперационных рубцов: № 2022622380: заявл. 29.09.2022: опубл. 06.10.2022; заявитель Федеральное государственное бюджетное научное учреждение «Российский научный центр хирургии имени академика Б.В. Петровского». EDN: SWAYKS

[23] Razumov AN, Knyazeva TA, Badtieva VA. Hypotensive and antianginal effects of laser therapy. Laser Med. 2001;5(1):22−25. EDN: PBZVQY

[24] Разумов А.Н., Князева Т.А., Бадтиева В.А. Гипотензивное и антиангинальное действие лазерной терапии // Лазерная медицина. 2001. Т. 5, № 1. С. 22−25. EDN: PBZVQY

[25] Razumov A, Knyazeva TA, Badtieva VA. Laser therapy as a method of eliminating tolerance to nitrates and potentiating their action. Problems Balneol Physiother Exercise Therapy. 2000;(5):3−5. EDN: VJAGDF

[26] Разумов А.Н., Князева Т.А., Бадтиева В.А. Лазеротерапия как метод устранения толерантности к нитратам и потенцирования их действия // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2000. № 5. С. 3−5. EDN: VJAGDF

[27] Ivanova GE, Melnikova EV, Shamalov NA, et al. Using the ICF and rating scales in medical rehabilitation. Bulletin Rehabilitat Med. 2018;(3):14–20. EDN: UTXLCY

[28] Иванова Г.Е., Мельникова Е.В., Шамалов Н.А., и др. Использование МКФ и оценочных шкал в медицинской реабилитации // Вестник восстановительной медицины. 2018. № 3. С. 14–20. EDN: UTXLCY

[29] Shoshmin AV, Ponomarenko GN. ICF in rehabilitation. 2nd revised and updated. Saint Petersburg; 2020. 232 p. EDN: UTPVBZ

[30] Шошмин А.В., Пономаренко Г.Н. МКФ в реабилитации. Изд. 2-е, перераб. и доп. Санкт-Петербург, 2020. 232 с.

[31] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1–464. EDN: THMJZZ doi: 10.4193/Rhin20.600

[32] Fokkens W.J., Lund V.J., Hopkins C., et al. European position paper on rhinosinusitis and nasal polyps 2020 // Rhinology. 2020. Vol. 58, Suppl. S29. P. 1–464. EDN: THMJZZ doi: 10.4193/Rhin20.600

[33] Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021;147(1):29–36. EDN: KNJTUD doi: 10.1016/j.jaci.2020.11.013

[34] Bachert C., Han J.K., Wagenmann M., et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management // J Allergy Clin Immunol. 2021. Vol. 147, N 1. P. 29–36. EDN: KNJTUD doi: 10.1016/j.jaci.2020.11.013

[35] Hanifin M, Rajka N. Diagnostic features of atopic dermatitis. Acta Dermatol Venerol. 1980;60(Suppl 92):44−47.doi: 10.2340/00015555924447

[36] Hanifin M., Rajka N. Diagnostic features of atopic dermatitis // Acta Dermatol Venerol. 1980. Vol. 60, Suppl. 92. P. 44–47. doi: 10.2340/00015555924447

[37] Paul WE. History of interleukin-4. Cytokine. 2015;75(1):3–7. EDN: YCQHRU doi: 10.1016/j.cyto.2015.01.038

[38] Paul W.E. History of interleukin-4 // Cytokine. 2015. Vol. 75, N 1. P. 3–7. EDN: YCQHRU doi: 10.1016/j.cyto.2015.01.038

[39] Le Floc'h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. EDN: TTRAUV doi: 10.1111/all.14151

[40] Le Floc'h A., Allinne J., Nagashima K., et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation // Allergy. 2020. Vol. 75, N 5. P. 1188–1204. EDN: TTRAUV doi: 10.1111/all.14151

[41] Ulashchik VS. Combined physical therapy: General information, interaction between physical factors. Problems Balneol Physiother Exercise Ther. 2016;(6):4–11. EDN: XHUGKX doi: 10.17116/kurort201664-11

[42] Улащик В.С. Сочетанная физиотерапия: общие сведения, взаимодействие физических факторов // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2016. Т. 93, № 6. С. 4–11. EDN: XHUGKX doi: 10.17116/kurort201664-11

[43] Benkov AA, Nagornev SN, Frolkov VK, et al. Analysis of the mechanisms of synergistic effects in the combined application of physiotherapeutic factors. Physiotherapist. 2021;(6):77–87. EDN: XDLLUA doi: 10.33920/med-14-2112-08

[44] Беньков, А.А., Нагорнев С.Н., Фролков В.К., и др. Анализ механизмов синергических эффектов при сочетанном применении физиотерапевтических факторов // Физиотерапевт. 2021. № 6. С. 77–87. EDN: XDLLUA doi: 10.33920/med-14-2112-08

[45] Ramos-Lopez O. Epigenetic biomarkers of metabolic responses to lifestyle interventions. Nutrients. 2023;15(19):4251. EDN: ONATKC doi: 10.3390/nu15194251

[46] Ramos-Lopez O. Epigenetic biomarkers of metabolic responses to lifestyle interventions // Nutrients. 2023. Vol. 15, N 19. P. 4251. EDN: ONATKC doi: 10.3390/nu15194251

[47] Morris BJ, Willcox BJ, Donlon TA. Genetic and epigenetic regulation of human aging and longevity. Biochim Biophys Acta Mol Basis Dis. 2019;1865(7):1718–1744. EDN: QQUNHU doi: 10.1016/j.bbadis.2018.08.039

[48] Morris B.J., Willcox B.J., Donlon T.A. Genetic and epigenetic regulation of human aging and longevity // Biochim Biophys Acta Mol Basis Dis. 2019. Vol. 1865, N 7. P. 1718–1744. EDN: QQUNHU doi: 10.1016/j.bbadis.2018.08.039

[49] Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis J Am Acad Dermatol. 2009;60(1):77–84. doi: 10.1016/j.jaad.2008.08.048

[50] Majoie I.M., Oldhoff J.M., van Weelden H., et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis // J Am Acad Dermatol. 2009. Vol. 60, N 1. P. 77–84. doi: 10.1016/j.jaad.2008.08.048

[51] Branisteanu DE, Dirzu DS, Toader MP, et al. Phototherapy in dermatological maladies (Review). Exp Ther Med. 2022;23(4):259. EDN: NZYGPC doi: 10.3892/etm.2022.11184

[52] Branisteanu D.E., Dirzu D.S., Toader M.P., et al. Phototherapy in dermatological maladies (Review) // Exp Ther Med. 2022. Vol. 23, N 4. P. 259. EDN: NZYGPC doi: 10.3892/etm.2022.11184

[53] Musters AH, Mashayekhi S, Harvey J, et al. Phototherapy for atopic eczema. Cochrane Database Syst Rev. 2021;10(10):CD013870. EDN: ZTYDZL doi: 10.1002/14651858.CD013870

[54] Musters A.H., Mashayekhi S., Harvey J., et al. Phototherapy for atopic eczema // Cochrane Database Syst Rev. 2021. Vol. 10, N 10. P. CD013870. EDN: ZTYDZL doi: 10.1002/14651858.CD013870

[55] Alexander H, Paller AS, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: Expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol. 2020;182(6):1331–1342.doi: 10.1111/bjd.18643

[56] Alexander H., Paller A.S., Traidl-Hoffmann C., et al. The role of bacterial skin infections in atopic dermatitis: Expert statement and review from the International Eczema Council Skin Infection Group // Br J Dermatol. 2020. Vol. 182, N 6. P. 1331–1342. doi: 10.1111/bjd.18643

[57] Nowicka D, Nawrot U. Contribution of Malassezia spp. to the development of atopic dermatitis. Mycoses. 2019;62(7):588–596. doi: 10.1111/myc.12913

[58] Nowicka D., Nawrot U. Contribution of Malassezia spp. to the development of atopic dermatitis // Mycoses. 2019. Vol. 62, N 7. P. 588–596. doi: 10.1111/myc.12913

Funding

ФГБУ «Клиническая больница № 1» УДП РоссииFederal State Budgetary Institution "Clinical Hospital No. 1" UDP of Russia.

RIGHTS & PERMISSIONS

Eco-Vector